Who Paid My Doc
Sixto Leal
Clinical Pathology/Laboratory Medicine Birmingham, AL Medical Doctor
NPI 1528488590 CMS profile 5175821
619 19Th St S, Birmingham, AL 35249
General payments
$9,044
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$185,691
Through program year 2025, Sixto Leal of Birmingham, AL is reported in the CMS Open Payments database as having received $9,044 across 5 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $185,691 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 87th percentile of Clinical Pathology/Laboratory Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,250 | 1 | |
| 2023 | General | $134 | 1 | |
| 2021 | General | $3,660 | 3 |
Beside peers
- Sixto Leal
- Clinical Pathology/Laboratory Medicine median
- Middle half of Clinical Pathology/Laboratory Medicine
- National median
In program year 2025, general payments to Sixto Leal were reported at $5,250. Among 206 Clinical Pathology/Laboratory Medicine profiles paid that year, the median was $114 and the middle half received between $43 and $2,190.
Show as a table
| Year | Sixto Leal | Clinical Pathology/Laboratory Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $100 | $25–$525 | $163 |
| 2020 | $0 | $127 | $24–$3,383 | $114 |
| 2021 | $3,660 | $124 | $28–$2,259 | $132 |
| 2022 | $0 | $100 | $36–$1,512 | $149 |
| 2023 | $134 | $125 | $30–$797 | $160 |
| 2024 | $0 | $127 | $30–$1,800 | $164 |
| 2025 | $5,250 | $114 | $43–$2,190 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Pathology/Laboratory Medicine in Alabama
Nirupama Singh
Clinical Pathology/Laboratory Medicine · Birmingham, AL
Jose Lima
Clinical Pathology/Laboratory Medicine · Hoover, AL
Nella Fernandez
Clinical Pathology/Laboratory Medicine · Montgomery, AL
Regan Cardamone
Clinical Pathology/Laboratory Medicine · Mobile, AL
Kelly Roveda
Clinical Pathology/Laboratory Medicine · Mobile, AL
Lee Fucich
Clinical Pathology/Laboratory Medicine · Mobile, AL
Related records
Clinical Pathology/Laboratory Medicine in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Pathology/Laboratory Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.